Changing the course of cancer treatment
We harness the power of the body's immune system to keep tumor cells in check without harming health or quality of life.
Mendus and Australasian Leukaemia & Lymphoma Group to expand clinical testing of vididencel as maintenance treatment for AML
Press Release Stockholm, Sweden, December 6, 2023 CADENCE Phase 2 trial will evaluate vididencel in combination with oral azacitidineRandomized controlled trial in 40 patients, with...
Mendus to present at Cell & Gene Therapy Manufacturing & Commercialization Conference in Dublin on December 4-6
Press Release Stockholm, Sweden, December 5, 2023 Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced it...
Mendus to Host KOL Event to Review Phase 2 Data with Vididencel in Acute Myeloid Leukemia Presented at ASH 2023 on December 14, 2023
Press Release Stockholm, Sweden, December 4, 2023 Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today...
Publication of Year-end Report 2022
Publication of Annual Report 2022
Annual General Meeting
Publication of Q1 Report
Publication of Q2 Report
Publication of Q3 Report
Publication of Year-end Report 2023
Keep up to date
Join our mailing list to receive our latest news.